Aprogen Biologics lends KRW 29.1 billion to Ainsfac at 4.6% interest
Bitget2026/09/23 07:27- Aprogen Biologics’ board on Sept. 23 resolved to extend a cash loan to Ainsfac.
- Loan set at KRW 29.1 billion, equal to 10.5% of equity based on year-end 2025 consolidated statements.
- Facility priced at 4.6%, scheduled to run from Sept. 28, 2026 to Sept. 27, 2027.
- Funding earmarked for strategic cash management to improve financial structure, with collateral to include Ainsfac investment interests.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
